Cargando…
Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis
Leishmaniasis affects around 12 million people worldwide and is estimated to cause the ninth-largest disease burden. There are three main forms of the disease, visceral (VL), cutaneous (CL), and mucocutaneous (MCL), leading to more than one million new cases every year and several thousand deaths. C...
Autores principales: | Bilbao-Ramos, Pablo, Serrano, Dolores R., Ruiz Saldaña, Helga Karina, Torrado, Juan J., Bolás-Fernández, Francisco, Dea-Ayuela, María Auxiliadora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144553/ https://www.ncbi.nlm.nih.gov/pubmed/32204358 http://dx.doi.org/10.3390/molecules25061394 |
Ejemplares similares
-
(E)-Piplartine Isolated from Piper pseudoarboreum, a Lead Compound against Leishmaniasis
por: Ticona, Juan C., et al.
Publicado: (2020) -
Nucleotides and AHCC Enhance Th1 Responses In Vitro in Leishmania-Stimulated/Infected Murine Cells
por: Dea-Ayuela, María Auxiliadora, et al.
Publicado: (2020) -
Therapeutic effect of ursolic acid in experimental visceral leishmaniasis
por: Jesus, Jéssica A., et al.
Publicado: (2016) -
Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
por: Bezerra-Souza, Adriana, et al.
Publicado: (2019) -
Preclinical Assessment of Ursolic Acid Loaded into Nanostructured Lipid Carriers in Experimental Visceral Leishmaniasis
por: Jesus, Jéssica Adriana, et al.
Publicado: (2021)